Adjuvant effect of IL-12: Conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo

Journal of Immunology

Volumn 163, Issue 5, 1999, Pages 2561-2567

  Schmidt, Clint S ^a   Mescher, Matthew F ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HERMES ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; BLAST TRANSFORMATION; BLOOD; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CLONE CELLS; FREUND'S ADJUVANT; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOLOGIC MEMORY; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OLIGOPEPTIDES; SOLUBILITY; TUMOR CELLS, CULTURED;

EID: 0033198139     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Dresser, D. W. 1962. Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. Immunology 5:378.
2. Aichele, P., D. Kyburz, P. S. Ohashi, B. Odermatt, R. M. Zinkernagel, H. Hengartner, and H. Pircher. 1994. Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc. Natl. Acad. Sci. USA 91:444.
3. Aichele, P., K. Brduscha-Riem, R. M. Zinkernagel, H. Hengartner, and H. Pircher. 1995. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182:261.
4. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991.
5. Janeway, C. A., C. C. Goodnow, and R. Medzhitov. 1996. Immunological tolerance: danger-pathogen on the premises! Curr. Biol. 6:519.
6. Dresser, D. W. 1961. Effectiveness of lipid and lipidophilic substances as adjuvants. Nature 191:1169.
7. Freund, J., J. Casals, and E. P. Hosmer. 1937. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med. 37:509.
8. Kyburz, D., P. Aichele, D. E. Speiser, H. Hengartner, R. M. Zinkemagel, and H. Pircher. 1993. T cell immunity after viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23:1956.
9. Kearney, E. R., K. A. Pape, D. Y. Loh, and M. K. Jenkins. 1994. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1:327.
10. Rojo, J. M., J. D. Kerner, and C. A. Janeway. 1989. Selective induction of growth factor production and growth factor receptor expression by different signals to a single T cell. Eur. J. Immunol. 19:2061.
11. + T cells. J. Immunol. 159:591.
12. Renauld, J., A. Vink, and J. V. Snick. 1989. Accessory signals in murine cytolytic T cell responses: dual requirement for IL-1 and IL-6. J. Immunol. 143:1894.
13. Okada, M., M. Kitahara, S. Kishimoto, T. Matsuda, T. Hirano, and T. Kishimoto. 1988. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J. Immunol. 141:1543.
14. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251.
15. Simon, M. M., S. Landolfo, T. Diamantstein, and U. Hochgeschwender. 1986. Antigen and lectin-sensitized murine cytolytic T lymphocyte precursors require both interleukin 2 and endogenously produced immune (γ) interferon for their growth and differentiation into effector cells. Curr. Top. Microbiol. Immunol. 126:173.
16. + T cells. J. Immunol. 162:3256.
17. + T cells. Annu. Rev. Immunol. 12:635.
18. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
19. Fallarino, F., C. Uyttenhove, T. Boon, and T. F. Gajewski. 1996. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156:1095.
20. Toda, M., R. L. Martuza, H. Kojima, and S. D. Rabkin. 1998. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160: 4457.
21. + T cells that expands in patients receiving interleukin-12. J. Clin. Invest. 102:561.
22. Leonard, J. P., M. L. Sherman, G. L. Fisher, L. J. Buchanan, G. Larsen, M. B. Atkins, J. A. Sosman, J. P. Dutcher, N. J. Vogelzang, and J. L. Ryan. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 90:2541.
23. + T cells upon in vivo stimulation with allogeneic tumor. J. Immunol. 159:650.
24. Sha, W. C., C. A. Nelson, R. D. Newberry, D. M. Kranz, J. H. Russell, and D. Y. Loh. 1988. Selective expression of an antigen receptor on CD8 bearing T lymphocytes in transgenic mice. Nature 335:271.
25. Magram, J., S. E. Connaughton, R. R. Warrier, D. M. Carvajal, C. Wu, J. Ferrante, C. Stewart, U. Sarmiento, D. A. Faherty, and M. K. Gately. 1996. IL-12-deficient mice are defective in IFNγ production and type 1 cytokine responses. Immunity 4:471.
26. Kranz, D. M., D. H. Sherman, M. V. Sitkovsky, M. S. Pastemack, and H. N. Eisen. 1984. Immunoprecipitation of cell surface structures of cloned cytotoxic T lymphocytes by clone-specific antisera. Proc. Natl. Acad. Sci. USA 81:573.
27. Udaka, K., K. Wiesmuller, S. Kienle, G. Jung, and P. Walden. 1996. Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J. Immunol. 157:670.
28. Dubois, P. M., M. Pihlgren, M. Tomkowiak, M. Van Mechelen, and J. Marvel. 1998. Tolerant CD8 T cells induced by multiple injections of peptide antigen show impaired TCR signaling and altered proliferative responses in vitro and in vivo. J. Immunol. 161:5260.
29. Bennett, S. R. M., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. A. P. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 393:478.
30. + T-helper and a T-killer cell. Nature 393: 474.
31. Schoenberger, S. P., R. E. M. Toes, E. I. H. van der Voort, R. Offringa, and C. J. M. Melief. 1998. T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
32. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.
33. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level of IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741.
34. Nanni, P., I. Rossi, C. D. Giovanni, L. Landuzzi, G. Nicoletti, A. Stoppacciaro, M. Parenza, M. P. Colombo, and P. Lollini. 1998. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res. 58:1225.
35. + T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J. Immunol. 162:609.
36. Gillies, S. D., Y. Lan, J. S. Wesolowski, X. Qian, R. A. Reisfeld, S. Holden, M. Super, and K. Lo. 1998. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostrate and colon carcinoma metastases. J. Immunol. 160: 6195.
37. Cavallo, F., E. D. Carlo, M. Butera, R. Verrua, M. P. Colombo, P. Musiani, and G. Forni. 1999. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res. 59: 414.
38. Ogawa, M., T. Tsutsui, J. Zou, J. Mu, R. Wijesuriya, W. Yu, S. Herrmann, T. Kubo, H. Fujiwara, and T. Hamaoka. 1997. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T cell migration to tumor sites following administration of interleukin 12. Cancer Res. 57:2216.